Cargando…

Early high-titer convalescent plasma therapy in patients with moderate and severe COVID-19

BACKGROUND AND OBJECTIVES: The use of COVID-19 convalescent plasma (CCP) has been approved by the FDA. We assessed the outcome of patients with moderate and severe COVID-19 following convalescent plasma therapy and the association with variables such as antibody titer in CCP units and transfusion ti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fazeli, Alieh, Sharifi, Shahin, Behdad, Fatemeh, Okati, Shamsi, Esmaielifar, Gilda, Jelveh, Nooshin, Eshghi, Peyman, Mohammadi, Saeed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612443/ https://www.ncbi.nlm.nih.gov/pubmed/34836825 http://dx.doi.org/10.1016/j.transci.2021.103321

Ejemplares similares

The demographic and serological characteristics of COVID-19 convalescent plasma donors: Identification of basic criteria for optimal donor selection
por: Fazeli, Alieh, et al.
Publicado: (2022)

Source Plasma Donation: The Experience of the Iranian Blood Transfusion Organization
por: Mohammadi, Saeed, et al.
Publicado: (2022)

Assessment of serological assays for identifying high titer convalescent plasma
por: Farnsworth, Christopher W., et al.
Publicado: (2021)

Assessment of serological assays for identifying high titer convalescent plasma
por: Farnsworth, Christopher W., et al.
Publicado: (2021)

Effect of time and titer in convalescent plasma therapy for COVID-19
por: de Candia, Paola, et al.
Publicado: (2021)

The Evidence for High-Titer Convalescent Plasma in SARS-CoV-2
por: Fisher, David L., et al.
Publicado: (2021)

Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study
por: Abolghasemi, Hassan, et al.
Publicado: (2020)

Coronavirus Disease 2019 Convalescent Plasma and the Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer
por: Bloch, Evan M, et al.
Publicado: (2021)

Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma
por: Franchini, Massimo, et al.
Publicado: (2022)

Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response
por: Herman, Jonathan D., et al.
Publicado: (2021)

Characteristics of High-Titer Convalescent Plasma and Antibody Dynamics After Administration in Patients With Severe Coronavirus Disease 2019
por: Bainbridge, Emma D, et al.
Publicado: (2021)

The predictors of high titer of anti-SARS-CoV-2 antibody of convalescent plasma donors
por: Wardhani, Shinta Oktya, et al.
Publicado: (2021)

Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma
por: Sullivan, David J., et al.
Publicado: (2021)

Analysis of anti-Omicron neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
por: Sullivan, David J, et al.
Publicado: (2022)

COVID-19 convalescent plasma boosts early antibody titer and does not influence the adaptive immune response
por: McDyer, John F., et al.
Publicado: (2023)

COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patients
por: Kasten, Mary J., et al.
Publicado: (2023)

Effects of Severe Acute Respiratory Syndrome Coronavirus 2 Strain Variation on Virus Neutralization Titers: Therapeutic Use of Convalescent Plasma
por: Nguyen, Dung, et al.
Publicado: (2021)

Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma
por: Donato, Michele L., et al.
Publicado: (2021)

Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy
por: Gontu, Abhinay, et al.
Publicado: (2021)

Pharmacokinetics of high-titer anti–SARS-CoV-2 human convalescent plasma in high-risk children
por: Gordon, Oren, et al.
Publicado: (2022)

Evaluation of SARS‐CoV‐2 antibody titers and potency for convalescent plasma donation: a brief commentary
por: Wouters, Elise, et al.
Publicado: (2020)

The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors
por: Kroemer, Marie, et al.
Publicado: (2022)

High-titer convalescent plasma plus nirmatrelvir/ritonavir treatment for non-resolving COVID-19 in six immunocompromised patients
por: Huygens, Sammy, et al.
Publicado: (2023)

Effect of convalescent plasma therapy on mortality in moderate-to-severely Ill COVID-19 patients
por: Agrawal, Akanksha, et al.
Publicado: (2022)

Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19
por: Briggs, Neima, et al.
Publicado: (2021)

Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2 In Vitro Virus Neutralization in Convalescent Plasma
por: Salazar, Eric, et al.
Publicado: (2020)

Administration of high titer convalescent anti-SARS-CoV-2 plasma: From donor selection to monitoring recipient outcomes
por: Mendoza, Rachelle P., et al.
Publicado: (2021)

Elevated cytokines and chemokines in peripheral blood of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma
por: Fanning, Stacey L., et al.
Publicado: (2021)

Correlation between ABO blood group and neutralizing anti-SARS-CoV-2 antibody titers in convalescent plasma donations
por: Franchini, M., et al.
Publicado: (2022)

Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
por: Sullivan, David J., et al.
Publicado: (2022)

Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial
por: Menichetti, Francesco, et al.
Publicado: (2021)

Assessment of High-Titer Convalescent Plasma as an Adjunctive Therapy in the Reduction of Mortality Rate and Viral Load in Patients with Severe COVID-19: A Meta-Analysis
por: Ramos, M.M., et al.
Publicado: (2022)

The clinical outcomes of high neutralizing antibodies titer convalescent plasma therapy in early developed severe COVID-19 patients; a case–control study
por: Nontawong, Nuttakant, et al.
Publicado: (2022)

Strangles, convalescent Streptococcus equi subspecies equi M antibody titers, and presence of complications
por: Delph, Katherine M., et al.
Publicado: (2018)

Positive anti-SARS-CoV-2 rapid serological test results among asymptomatic blood donors
por: Arabkhazaeli, Ali, et al.
Publicado: (2022)

Mid-titer human convalescent plasma administration results in suboptimal prophylaxis against SARS-CoV-2 infection in rhesus macaques
por: Beddingfield, Brandon J., et al.
Publicado: (2023)

A comparison between on-demand usage of rFVIIa vs prophylaxis use of emicizumab in high titer inhibitory hemophilia A patients in Iran: A cost–utility analysis
por: Saiyarsarai, Parisa, et al.
Publicado: (2021)

Early administration of COVID‐19 convalescent plasma with high titer antibody content by live viral neutralization assay is associated with modest clinical efficacy
por: Belov, Artur, et al.
Publicado: (2022)

The Relationship Between SARS-CoV-2 Neutralizing Antibody Titers and Avidity in Plasma Collected From Convalescent Nonvaccinated and Vaccinated Blood Donors
por: Nurmi, Visa, et al.
Publicado: (2023)

Efficacy of convalescent plasma for the treatment of severe influenza
por: Xu, Zhiheng, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_o17ivc9u7720av81i1qro41stt